



2017 Eligible Measure Applicability (EMA) for Claims Data Submission of Individual Quality Measures

2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR CLAIMS DATA SUBMISSION

QPP Clinically Related Measures Analysis Used in EMA

Step 1: Clinical Relation including an Outcome/High Priority Test of the 2017 Claims Data Submission of Individual Quality Measures

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
1	Urinary Incontinence Care	48	N/A	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
		50	High Priority	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older
2	Diabetic Care	1	Intermediate Outcome	Diabetes: Hemoglobin A1c Poor Control
		117	N/A	Diabetes: Eye Exam
		128	N/A	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
		Note: When submitting #117, it is not subject to EMA for these clinically related measures. It is expected to submit #1 and #128, if #117 is submitted.		
3	Lung Care	51	N/A	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation
		52	N/A	Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy
		130	High Priority	Documentation of Current Medications in the Medical Record
4	Emergency Care	254	N/A	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain
		255	N/A	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure
5	Ear, Nose, & Throat Care	91	High Priority	Acute Otitis Externa (AOE): Topical Therapy
		93	High Priority	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use
6	Pathology	99	N/A	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
		100	N/A	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
		249	N/A	Barrett's Esophagus
		250	N/A	Radical Prostatectomy Pathology Reporting
		251	N/A	Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients
7	Diagnostic Imaging	145	High Priority	Radiology: Exposure Dose or Time Reported for Procedures Using Fluoroscopy

2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR CLAIMS DATA SUBMISSION

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
		146	High Priority	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening
		147	High Priority	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy
		195	N/A	Radiology: Stenosis Measurement in Carotid Imaging Reports
		225	High Priority	Radiology: Reminder System for Screening Mammograms
		436	N/A	Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques
8	Appropriate Follow-Up Imaging	405	High Priority	Appropriate Follow-Up Imaging for Incidental Abdominal Lesions
		406	High Priority	Appropriate Follow-Up Imaging for Incidental Thyroid Nodules in Patients
9	Eye Care	12	N/A	Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
		14	N/A	Age-Related Macular Degeneration (AMD): Dilated Macular Examination
		19	High Priority	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
		117	N/A	Diabetes: Eye Exam
		140	N/A	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement
		141	Outcome	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care
10	Surgical Care	21	High Priority	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
		23	High Priority	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
		47	High Priority	Care Plan
11	Chiropractic Care	131	High Priority	Pain Assessment and Follow-Up
		182	High Priority	Functional Outcome Assessment
12	Pathology Lung Cancer	395	Outcome	Lung Cancer Reporting (Biopsy/ Cytology Specimens)
		396	Outcome	Lung Cancer Reporting (Resection Specimens)

2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR CLAIMS DATA SUBMISSION

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
13	Gynecological Care	422	High Priority	Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury
		432	Outcome	Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair
		433	Outcome	Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair
		434	Outcome	Proportion of Patients Sustaining a Ureter Injury at the Time of any Pelvic Organ Prolapse Repair
14	Headache Care	419	High Priority	Overuse of Neuroimaging for Patients with Primary Headache And a Normal Neurological Examination
		435	Outcome	Quality of Life Assessment for Patients with Primary Headache Disorders
15	Immunization Care	110	N/A	Preventive Care and Screening: Influenza Immunization
		111	N/A	Pneumococcal Vaccination Status for Older Adults
16	General Care	130	High Priority	Documentation of Current Medications in the Medical Record
		226	N/A	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		134	N/A	Preventive Care and Screening: Screening for Depression and Follow-Up Plan
		317	N/A	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
		Note: When submitting #130 and/or #226, they are not subject to EMA for these clinically related measures. It is expected to submit #130, #226, if quality measures if #134 and/or #317 is submitted.		
17	Preventive Care	112	N/A	Breast Cancer Screening
		113	N/A	Colorectal Cancer Screening
		130	High Priority	Documentation of Current Medications in the Medical Record
		317	N/A	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
		Note: When submitting #130 or #317, they are not subject to EMA for these clinically related measures. It is expected to submit #130 and #317, if #112 and/or #113 are submitted. There is no requirement for both #112 and #113 to be submitted.		

2017 ELIGIBLE MEASURE APPLICABILITY (EMA) FOR CLAIMS DATA SUBMISSION

Number	Title	Quality ID	Outcome/High Priority	Quality Measure Title
18	Colonoscopy Care	130	High Priority	Documentation of Current Medications in the Medical Record
		425	N/A	Photodocumentation of Cecal Intubation
		<i>Note: When submitting #130, it is not subject to EMA for these clinically related measures. If quality measure #425 is submitted, it is expected to submit #130.</i>		
19	Endoscopy and Polyp Surveillance	185	High Priority	Colonoscopy Interval for Patients with a History of Adenomatous Polyps — Avoidance of Inappropriate Use
		320	High Priority	Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients